An observational study in Obstructive Coronary Artery Disease and Left Ventricular Hypertrophy, sponsored by University of Pisa. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Pisa · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertrophy, Left Ventricular with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hypertrophy, Left Ventricular · Italy.
Among the 14 studies in Hypertrophy, Left Ventricular with a site in Italy, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 14th registered.
162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.
Browse Hypertrophy, Left Ventricular studies →3 of the 14 studies in Hypertrophy, Left Ventricular with a site in Italy are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Italy, United States, Brazil and 6 more countries
Ages 6+
Rocket Pharmaceuticals Inc. · Sites in Italy, United States, Germany and 1 more country
Ages 8+ · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 20 Hypertrophy, Left Ventricular studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 198 across 60 observational studies indexed under Hypertrophy, Left Ventricular.
Median enrollment 164 across the 12 interventional studies, 340 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 10 most frequent:
University of Pisa is the lead sponsor of 113 studies on the registry; 28 are open to participants now.
University of Pisa has 1 study filed under Hypertrophy, Left Ventricular — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hypertrophy, Left Ventricular with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the ability of exercise ECG to discriminate between hypertensive heart disease-related and CAD-related abnormalities
In this prospective study, consecutive patients undergoing evaluation for suspected coronary artery disease will undergo exercise ECG testing (ExECG), transthoracic echocardiography (TTE), stress cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA).
Patients will be stratified into four groups according to the presence or absence of LVH and obstructive CAD:
LVH with obstructive CAD LVH without obstructive CAD No LVH with obstructive CAD No LVH without obstructive CAD
LVH will be defined by standard echocardiographic criteria, while obstructive CAD will be assessed by CCTA. Stress CMR will serve as the reference standard for inducible myocardial ischemia.
Exercise ECG parameters will include conventional ST-segment criteria as well as dynamic indices during exercise and recovery. Associations between ECG findings and imaging-defined phenotypes will be evaluated, and predictors of CAD-related ischemia will be identified.
Results The study will assess the diagnostic performance of exercise ECG across the four predefined groups. Differences in ECG response patterns will be compared according to the presence of LVH and obstructive CAD. Multivariable analysis will be performed to identify independent ECG predictors associated with obstructive CAD and inducible ischemia.
consecutive patients undergoing evaluation for suspected coronary artery disease will undergo exercise ECG testing (ExECG), transthoracic echocardiography (TTE), stress cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA).
Patients will be stratified into four groups according to the presence or absence of LVH and obstructive CAD:
LVH with obstructive CAD LVH without obstructive CAD No LVH with obstructive CAD No LVH without obstructive CAD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
LVH with obstructive CAD
LVH without obstructive CAD
No LVH with obstructive CAD
No LVH without obstructive CAD
diagnostic performance of exercise ECG across the four predefined groups.
Differences in ECG response patterns will be compared according to the presence of LVH and obstructive CAD. Multivariable analysis will be performed to identify independent ECG predictors associated with obstructive CAD and inducible ischemia.
Time frame: From enrollment through completion of all diagnostic evaluations, assessed up to 3 months after enrollment.
Plan to share: No — Individual participant data (IPD) will be made available upon reasonable request following the completion of all planned analyses and subsequent publication of the resulting manuscripts
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
Of 18 observational studies under Hypertrophy, Left Ventricular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 58. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypertrophy, Left Ventricular →